On May 27, 2021, Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model to discover, develop, and ultimately deliver impactful medicines to patients, announced the pricing of its initial public offering of 16,500,000 American Depositary Shares (ADSs), each representing one ordinary share at a public offering price of $20.00 per ADS. All of the ADSs are being offered by Centessa.

The gross proceeds to Centessa from the offering, before deducting underwriting discounts, commissions, and other estimated offering expenses, are expected to be approximately $330 million. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,475,000 ADSs at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Select Market under the ticker symbol “CNTA” on May 28, 2021. The offering is expected to close in June 2021, subject to customary closing conditions.

A Wilson Sonsini team that was led by Julia Minitti and included Mike Hostetler advised Centessa on patent matters related to the IPO.

For more information, please see Centessa's press release.